SG11201502816YA - Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics - Google Patents

Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics

Info

Publication number
SG11201502816YA
SG11201502816YA SG11201502816YA SG11201502816YA SG11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA SG 11201502816Y A SG11201502816Y A SG 11201502816YA
Authority
SG
Singapore
Prior art keywords
production
recombinant antibody
signal peptides
antibody therapeutics
heavy chain
Prior art date
Application number
SG11201502816YA
Other languages
English (en)
Inventor
Zhiwei Song
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG11201502816YA priority Critical patent/SG11201502816YA/en
Publication of SG11201502816YA publication Critical patent/SG11201502816YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
SG11201502816YA 2012-10-12 2013-08-21 Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics SG11201502816YA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201502816YA SG11201502816YA (en) 2012-10-12 2013-08-21 Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2012076295 2012-10-12
SG11201502816YA SG11201502816YA (en) 2012-10-12 2013-08-21 Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
PCT/SG2013/000360 WO2014058389A1 (fr) 2012-10-12 2013-08-21 Peptides signal à chaîne lourde et à chaîne légère optimisés permettant de produire des agents thérapeutiques à base d'anticorps recombinants

Publications (1)

Publication Number Publication Date
SG11201502816YA true SG11201502816YA (en) 2015-05-28

Family

ID=50477711

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502816YA SG11201502816YA (en) 2012-10-12 2013-08-21 Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics

Country Status (5)

Country Link
US (1) US10066019B2 (fr)
EP (1) EP2906599B1 (fr)
CN (1) CN104854133B (fr)
SG (1) SG11201502816YA (fr)
WO (1) WO2014058389A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2906599B1 (fr) 2012-10-12 2019-07-17 Agency For Science, Technology And Research Peptides signal à chaîne lourde et à chaîne légère optimisés permettant de produire des agents thérapeutiques à base d'anticorps recombinants
KR102092225B1 (ko) * 2014-04-30 2020-03-23 주식회사 엘지화학 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
CN105820246A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型重组抗TNFα嵌合单克隆抗体制备方法及用途
WO2016123160A1 (fr) * 2015-01-26 2016-08-04 Biotech Institute, Llc Systèmes, appareils et procédés de classification
US10894083B2 (en) * 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
RU2745748C2 (ru) 2016-06-02 2021-03-31 Эббви Инк. Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
US11951207B2 (en) * 2016-06-30 2024-04-09 Celltrion Inc. Stable liquid pharmaceutical preparation
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
WO2019055471A1 (fr) * 2017-09-18 2019-03-21 Amyris, Inc. Procédés de production d'anticorps pleine longueur
CN107488636A (zh) * 2017-09-30 2017-12-19 山东兴瑞生物科技有限公司 一种携带分子开关的抗her2嵌合抗原受体修饰的免疫细胞及其应用
MA49796A (fr) 2017-12-01 2020-06-03 Abbvie Inc Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
JP7072792B2 (ja) * 2017-12-11 2022-05-23 国立大学法人神戸大学 二重特異性抗体
US11447547B1 (en) * 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
CN108103088B (zh) * 2017-12-21 2021-03-26 广东东阳光药业有限公司 重组GLP-1类似物Fc融合蛋白的优化基因及其应用
CA3123177A1 (fr) 2018-12-21 2020-06-25 Kymab Limited Anticorps bispecifique fixaxfx avec chaine legere commune
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies
JP2022532388A (ja) * 2019-05-15 2022-07-14 カイマブ・リミテッド 改善されたラムダ抗体
CN111072764A (zh) * 2019-12-13 2020-04-28 东莞市东阳光生物药研发有限公司 一种重组人Activin A的制备方法
SE543999C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Dna construct for expressing a novel signal peptide
SE544006C2 (en) * 2020-03-17 2021-11-02 Xbrane Biopharma Ab Novel combination of tis sequence and signal peptide sequence for expressing a recombinant protein
WO2021188034A1 (fr) * 2020-03-17 2021-09-23 Xbrane Biopharma Ab Nouvelle combinaison de séquence tis et séquence de peptide signal pour exprimer une protéine recombinée
SE543998C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Dna construct for expressing nivolumab
KR102457344B1 (ko) * 2020-06-22 2022-10-24 건국대학교 글로컬산학협력단 항암 펩티드와 결합된 항원결합단편 플랫폼
CA3191184A1 (fr) * 2020-08-28 2022-03-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Peptide signal pour reduire l'heterogeneite finale d'un polypeptide heterologue
CN114574444B (zh) * 2020-12-01 2024-05-03 达达生物技术(北京)有限公司 自体纤维母细胞在制备抗类风湿关节炎药物中的应用
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
WO2023081733A1 (fr) * 2021-11-02 2023-05-11 Washington University Compositions et méthodes de traitement anticancéreux
WO2023220118A2 (fr) * 2022-05-10 2023-11-16 Regenerative Research Foundation Compositions et méthodes de dégradation contrôlée de protéines dans une maladie neurodégénérative

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506132A (en) 1993-07-28 1996-04-09 Sandoz Pharmaceuticals Corporation Human antibodies against varicella-zoster virus
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
AU2003282667A1 (en) * 2002-10-03 2004-04-23 Large Scale Biology Corporation Multimeric protein engineering
PL1648998T3 (pl) * 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
CN101292036B (zh) 2005-10-21 2016-04-13 弗·哈夫曼-拉罗切有限公司 用于重组表达多肽的方法
US20090208491A1 (en) 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
WO2010108153A2 (fr) 2009-03-20 2010-09-23 Amgen Inc. Immunoglobulines porteuses et utilisations de celles-ci
RU2012122240A (ru) * 2009-10-30 2013-12-10 Эбботт Лэборетриз Конструкции sorf и экспрессия нескольких генов
EP2906599B1 (fr) 2012-10-12 2019-07-17 Agency For Science, Technology And Research Peptides signal à chaîne lourde et à chaîne légère optimisés permettant de produire des agents thérapeutiques à base d'anticorps recombinants

Also Published As

Publication number Publication date
US20150225482A1 (en) 2015-08-13
CN104854133B (zh) 2018-10-30
EP2906599B1 (fr) 2019-07-17
CN104854133A (zh) 2015-08-19
EP2906599A1 (fr) 2015-08-19
EP2906599A4 (fr) 2016-04-27
US10066019B2 (en) 2018-09-04
WO2014058389A1 (fr) 2014-04-17

Similar Documents

Publication Publication Date Title
SG11201502816YA (en) Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
IL287270A (en) Anti-psgl-1 antibodies and their use
IL292121A (en) Anti-plasma kallikrein antibodies
HK1206636A1 (en) Modified polynucleotides for the production of oncology-related proteins and peptides
HK1210027A1 (en) Anti-human b7-h4 antibodies and their uses b7-h4
IL230918A0 (en) Modified proteins and peptides
IL224441B (en) Antibodies with modified isoelectric points
EP2904093A4 (fr) Procédés de quantification de paires polypeptidiques de chaînes lourdes et légères
SG11201404751UA (en) Modified fc region of antibody
HK1215446A1 (zh) 抗體及其用途
EP2832855A4 (fr) Nouvel anticorps anti-siglec-15
HK1208810A1 (en) C-terminal and central epitope a-beta antibodies c a-
EP2726103A4 (fr) Anticorps anti-properdine et leurs utilisations
SG11201403814RA (en) Production of recombinant proteins with simple glycoforms
HK1222871A1 (zh) 具有最小單體分離的重組多克隆抗體多聚體的分離
HK1220492A1 (zh) 重組多肽生產
EP2678440A4 (fr) Souche de levure pour la production de protéines avec une o-glycosylation modifiée
IL234394A0 (en) Recombinant antibodies with dual specificity for gangliosides and their use
EP2688913A4 (fr) Production à haut niveau de protéines recombinantes
EP2771689A4 (fr) Peptides usp2a et anticorps
EP2726614A4 (fr) Amélioration de la production de protéines étrangères
IL266073B (en) Heterodimeric antibody fccontaining proteins and methods for production thereof
HK1211952A1 (en) Recombinant protein
GB201121233D0 (en) Modified proteins and peptides
GB201121226D0 (en) Modified proteins and peptides